WAISMAN BIOMANUFACTURING

Company Snapshot

Founded: 2001
Entity Type: Private
Region: U.S.
Headquarter: Wisconsin, U.S.
Key Geographics: U.S.
Corporate Address: 1500 Highland Avenue Madison Wisconsin 53705 U.S. Tel. +1-608-262-9547 www.gmpbio.org

Company Overview

Waisman Biomanufacturing is focused on offering cGMP manufacturing services for clinical or industrial institutions in the development of novel biological therapies for clinical trials. The company opened its cGMP facility in 2001 and has manufactured more than 300 clinical-grade products. Waisman Biomanufacturing has established processes for banking iPSCs in collaboration with Cellular Dynamics Inc. It will use the iPSC banks made under cGMP conditions to produce iPSC-derived cells for clinical trials.

WAISMAN BIOMANUFACTURING In Reports

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028 at a CAGR of 9.1%.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate of 9.3%.

Induced Pluripotent Stem Cells: Global Markets

The global induced pluripotent stem cells (iPSC) market should reach $3.8 billion by 2024 from $2.4 billion in 2019 at a compound annual growth rate (CAGR) of 9.2% for the forecast period of 2019 to 2024. ...

WAISMAN BIOMANUFACTURING In News

Company's Business Segments

  • cGMP Manufacturing Services : This service includes Process Development, GMP Manufacturing, Quality Control, QA and Regulatory Support, Clinical Production.

Applications/End User Industries

  • Researchers
  • Clinicians
  • Pharmaceutical
  • Healthcare
  • Cell and Gene Therapies
  • Biotech Companies
  • Biotherapeutics
  • Adherent Manufacturing
  • Plasmid DNA